Coupling his core background in security law with a pioneering spirit, Amarin Corp. executive vice president and general counsel Joseph Kennedy continues to lead his pharmaceutical company into new frontiers of legal advocacy.

Kennedy said he joined Dublin-based Amarin as general counsel in 2011 primarily to help secure patents and implement a compliance program as the company awaited U.S. Food and Drug Administration approval of its blockbuster cardiovascular drug, Vascepa. Little did he know then that regulatory roadblocks and other challenges would force him to become a legal trailblazer.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]